Factor H is difficult to manufacture at scale with traditional methods
In the long human effort to tame diseases that medicine has largely passed over, a German biotech company has brought a rare kidney condition one step closer to a real answer. Eleva's CPV-104 — a laboratory-crafted version of a protein the immune system needs to police itself — has moved from healthy volunteers into patients whose kidneys are actively failing from C3 glomerulopathy, a disease where the body's own complement pathway turns destructive. The therapy is the only one of its kind in clinical development, born from an unconventional manufacturing method that uses moss as a biological factory, and its progress into patient trials marks a rare moment of possibility for a population that has had very few.
- C3 glomerulopathy quietly destroys kidney function in patients who have almost no targeted therapies to turn to, making every step toward a viable treatment carry unusual weight.
- CPV-104 cleared its first human hurdle cleanly — 21 healthy volunteers across four escalating dose groups showed no safety concerns, giving regulators and reviewers confidence to move forward.
- The trial now shifts to 18 patients with active disease, a multiple ascending dose study that will test whether the drug's promising preclinical behavior — normalizing complement proteins and clearing kidney deposits — holds in the people who actually need it.
- Eleva's moss-based manufacturing platform is itself under scrutiny: Factor H has long resisted large-scale production through conventional methods, and the company's ability to produce it at all is what made this trial possible.
- With EU Orphan Drug Designation secured and a second drug candidate already through Phase 1b, Eleva is positioning itself as a serious player in biologics manufacturing — but the current trial's results will determine whether innovation in the factory translates into healing in the clinic.
A German biotech company has moved a rare kidney disease therapy into patient trials after clearing an important early safety threshold. Eleva's CPV-104 — a recombinant version of the human protein Factor H — completed single ascending dose testing in 21 healthy volunteers across four cohorts without triggering any safety concerns. A review committee, satisfied with the clean data, approved the transition to the next phase.
Eighteen patients with C3 glomerulopathy will now receive the drug over four weeks in a multiple ascending dose study. C3G is a condition in which the immune system's complement pathway becomes dysregulated, depositing inflammatory material in the kidney's filtering structures and steadily eroding function. Treatment options are scarce, and the European Union has granted CPV-104 orphan drug status in recognition of both the disease's rarity and the absence of adequate existing therapies.
What distinguishes CPV-104 is as much about manufacturing as medicine. Factor H is notoriously difficult to produce at scale through conventional biological methods. Eleva has built its platform around moss as a biological factory — a system capable of producing complex proteins that standard approaches struggle to replicate. CPV-104 is the second candidate from this platform to enter human testing, following a Fabry disease treatment that has already completed its own Phase 1b trial.
In preclinical studies, CPV-104 normalized complement protein levels in the blood and helped clear pathogenic deposits from kidney tissue. Whether those effects will hold in living patients is what the current trial is designed to reveal. The study is small and early, but it represents the first time this approach to complement-mediated kidney disease has been tested in the people it is meant to help — and the results will determine whether a manufacturing breakthrough can become a clinical one.
A German biotech company has cleared a significant hurdle in developing a therapy for a rare kidney disease that has few treatment options. Eleva announced in October that CPV-104, a laboratory-made version of a human protein called Factor H, has moved from early safety testing in healthy people into trials with actual patients who have C3 glomerulopathy, a condition where the immune system's complement pathway spirals out of control and damages the kidneys.
The path to this milestone began with 21 healthy volunteers who received escalating doses of CPV-104 across four separate groups. A safety review committee examined the data and found no concerning signals—no dose-limiting toxicities, no unexpected reactions. That clean safety record gave the committee confidence to approve the next phase. Now eighteen patients with C3G will receive the drug over a four-week period in what researchers call a multiple ascending dose study, essentially repeating the dose-escalation approach but this time in people whose kidneys are actually failing from the disease.
What makes CPV-104 noteworthy is not just what it does but how it is made. Factor H is notoriously difficult to manufacture at scale using the standard methods that dominate the biologics industry—Chinese hamster ovary cells, yeast fermentation, other conventional platforms. Eleva has built its entire company around a different approach: using moss as a biological factory. The moss-based system can produce complex proteins that other methods struggle with, and CPV-104 is the second drug candidate to emerge from this platform into human testing. The first, a treatment for Fabry disease, has already completed its own Phase 1b trial.
C3G itself is a narrow target. The disease strikes when the complement system, part of the immune response, becomes dysregulated and begins depositing inflammatory material in the kidney's filtering structures. Patients lose kidney function. Treatment options are sparse. The European Union has granted CPV-104 orphan drug status, a designation reserved for therapies addressing diseases that affect fewer than five in ten thousand people and have no adequate existing treatments.
In preclinical work, CPV-104 behaved like the real Factor H—it normalized levels of a complement protein called C3 in the blood and helped clear pathogenic deposits from the kidney tissue. Whether it will do the same in living patients is what the current trial will reveal. Dr. Martin Bauer, Eleva's chief medical officer, framed the moment carefully: the healthy volunteer data was encouraging, but the real test comes now, in the people who need it. Björn Cochlovius, the company's CEO, emphasized that the moss platform's ability to manufacture Factor H at scale represents a competitive advantage in a field where traditional methods have hit a wall.
The trial is small—eighteen patients across three dose groups—and it is early. But it represents the first time this particular approach to treating complement-mediated kidney disease has been tested in the people it is meant to help. The results will determine whether Eleva's manufacturing innovation translates into clinical benefit, and whether patients with C3G finally have a targeted option beyond the limited arsenal currently available.
Notable Quotes
We are highly encouraged by the favorable safety profile observed in healthy volunteers. As we initiate patient cohorts now, we look forward to generating solid data to demonstrate the potential of CPV-104 to modify the course of complement mediated kidney diseases.— Dr. Martin Bauer, Chief Medical Officer of Eleva
Factor H is difficult to manufacture at scale with traditional CHO and yeast processes. Being able to produce these complex proteins at scale underscores our differentiated position in biologics manufacturing.— Björn Cochlovius, Chief Executive Officer of Eleva
The Hearth Conversation Another angle on the story
Why does it matter that this drug is made in moss rather than the usual way?
Because Factor H is a large, complex protein with specific folding requirements. The standard manufacturing systems—hamster cells, yeast—struggle to produce it at the scale you'd need for a real medicine. Moss can do it. That's not just a technical win; it's the difference between a drug that exists in theory and one that can actually be made and distributed.
What is C3 glomerulopathy, and why is it so hard to treat?
It's a rare kidney disease where the complement system—part of your immune response—goes haywire and attacks your own kidney tissue. The disease is progressive and damages the filtering structures. Right now there's no targeted therapy. Doctors manage symptoms, but they can't stop the underlying process. That's why orphan drug status matters here—there's genuine medical need with almost no options.
The trial moved from healthy volunteers to patients very quickly. Is that safe?
The healthy volunteer phase is designed to establish that the drug itself isn't toxic—that it doesn't cause unexpected harm at any dose level. Once you have clean safety data there, moving to patients with the actual disease is the logical next step. The patients in this trial are still getting carefully escalated doses, so it's not reckless. It's the standard path.
What happens if the drug works in these eighteen patients?
Then Eleva would have evidence that CPV-104 can actually modify the disease in the people it's meant to help. That would likely lead to larger, more rigorous trials. If those go well, they'd seek regulatory approval. But we're still in the early phase. Eighteen patients is enough to learn about safety and get hints about efficacy, but not enough to prove the drug works.
Why emphasize the moss manufacturing so much in the announcement?
Because it's Eleva's core differentiation. Any company can run a clinical trial. But if you're the only one who can manufacture Factor H at scale, you have a genuine moat. The CEO is signaling to investors and partners that this isn't just about one drug—it's about a platform that can produce other difficult proteins that competitors can't touch.